Iovance Biotherapeutics Securities Fraud: Join the Class Action Now
July 7, 2025 – New York
The Rosen Law Firm, well-known for championing investor rights globally, has announced a reminder for purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities. Those who acquired their shares between May 9, 2024, and May 8, 2025, are urged to consider participating in a securities fraud class action lawsuit. The deadline for interested investors to step forward is
July 14, 2025.
Why Act Now?
If you acquired Iovance securities during the stated class period, you might be eligible for compensation without any initial costs through a contingency fee agreement. This means you won’t have to worry about out-of-pocket expenses—your legal fees will only be payable once a recovery is made.
To join this class action ahead of the deadline, simply visit the following link:
Join Iovance Class Action. For additional inquiries, you can contact Phillip Kim, Esq. at
866-767-3653 or via email at
[email protected]. A class action lawsuit has already been initiated, and if you wish to become the lead plaintiff, it’s crucial to file your intentions in court no later than the deadline mentioned.
Background of the Case
The lawsuit alleges that throughout the class period, Iovance’s management made several false and misleading statements or failed to disclose critical facts.
- - Inefficient Treatment Start Times: New Authorized Treatment Centers (ATCs) reportedly faced delays in beginning patient treatments with their product, Amtagvi.
- - Sales and Identification Failures: There were issues with the sales team and ATCs being ineffective in identifying and selecting suitable patients for treatment, resulting in increased patient drop-offs.
- - Financial Performance Impacted: These operational setbacks led to escalated costs and diminished revenues, as ATCs struggled to manage the volume of manufactured products appropriately.
- - Misleading Positive Statements: As a result of these dynamics, the optimistic portrayals made by Iovance regarding their business, operations, and future prospects were said to be materially deceptive and lacked a rational basis.
When the true circumstances come to light, the lawsuit contends that investors were left suffering notable financial losses.
Choosing the Right Legal Counsel
The Rosen Law Firm advocates for investors to choose capable legal representation with a robust record in leading similar lawsuits. They highlight that many firms, while issuing notices, lack the experience or reputation to handle significant investor cases effectively. Often, these firms engage only in referring clients to others who might litigate their cases.
The Rosen Law Firm focuses on securities class actions and has made significant recoveries for investors, including notable $438 million achieved in 2019 alone. They have a reputation etched in success, being rated among the top firms in the securities class action field.
Next Steps for Investors
To proceed with the Iovance class action, click here:
Join Iovance Class Action
or feel free to reach out to Phillip Kim at
866-767-3653 or via email at
[email protected]. Keep in mind that until a class is officially certified by the court, participants remain unrepresented unless they choose to retain their legal counsel. You can also opt to stay as an absent class member at this phase if preferred.
For real-time updates, follow the Rosen Law Firm across their social media platforms:
Please Note: This communication is considered attorney advertising. Past results do not ensure similar outcomes in future cases.